CJC-1295: A Literature Course in Six Modules

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question. It summarises what published studies on CJC-1295 reported. Nothing here is a protocol, a recommendation, or a claim that any outcome will occur in any individual.

How this course is organised

Six modules move from identity to regulation. Every module closes with a short section on what the underlying evidence cannot support. The sources are a small set of primary papers: pharmacology work in rats and mice, phase-I-style dosing studies in healthy adults, forensic and anti-doping analytical papers, and one qualitative study of online discussion. There is no large outcome trial in this literature, and the course does not pretend otherwise.

Module 1: What CJC-1295 Is and How It Has Been Studied

Definition and class

CJC-1295 belongs to the class of growth hormone-releasing hormone (GHRH) analogs — also written GRF analogs. Its peptide backbone is derived from human growth hormone-releasing factor 1-29, the shortest fragment of GHRH that retains full biological activity at the pituitary GRF receptor. The defining modification is a reactive chemical group that allows the peptide to form a covalent bioconjugate with circulating albumin; the 2005 rat study that characterised hGRF(1-29)-albumin bioconjugates identified CJC-1295 as a long-lasting GRF analog that activated the GRF receptor on the anterior pituitary (PMID 15817669).

Origin

The compound emerged from drug-development chemistry aimed at solving the short half-life of native GHRH. The 2005 Endocrinology paper described the bioconjugate strategy and the identification of CJC-1295 among the candidates tested in rats (PMID 15817669). Subsequent work moved into a genetic mouse model: once-daily administration of CJC-1295 normalised growth in the GHRH knockout mouse, as reported in 2006 (PMID 16822960).

Forms encountered in the literature

Two naming conventions circulate. In the peer-reviewed pharmacology literature, "CJC-1295" refers to the albumin-binding (drug-affinity-complex) version described in the 2005 rat work (PMID 15817669). Outside that literature, the label is also applied to a modified GRF(1-29) without the albumin-binding group. The verified papers here do not compare those two entities head to head, so this course does not attribute any published result to the non-conjugated version. Analytical chemistry has also had to grapple with unlabelled material: a 2010 paper reported the identification of CJC-1295 in an unknown pharmaceutical preparation submitted for analysis (PMID 21204297).

Limits of the evidence in Module 1: the identity literature is small and largely analytical. There is no published head-to-head characterisation of the different products sold under the CJC-1295 name, no long-term chemistry-and-stability dataset in the verified set, and no approved reference product against which unknown preparations can be compared.

Module 2: Mechanism as Described in the Literature

Receptor step

The proposed mechanism is receptor-level and indirect. GHRH analogs act at the GRF receptor on somatotroph cells of the anterior pituitary; binding stimulates the synthesis and release of endogenous growth hormone rather than supplying growth hormone itself. The 2005 rat study demonstrated that the hGRF(1-29)-albumin bioconjugates activated that receptor in vivo (PMID 15817669).

Why albumin binding matters

Native GHRH is cleared quickly. Covalent attachment to albumin was the strategy used to extend exposure, and the 2005 paper identified CJC-1295 specifically as the long-lasting candidate from that series (PMID 15817669). Prolonged receptor stimulation is what distinguishes the analog from short-acting GHRH in these reports.

Downstream axis

Because growth hormone drives hepatic production of insulin-like growth factor I, the expected downstream marker is IGF-I. The 2006 study in healthy adults reported prolonged stimulation of both GH and IGF-I secretion after CJC-1295 administration (PMID 16352683). A separate 2009 analysis described activation of the GH/IGF-1 axis by CJC-1295 producing serum protein profile changes in normal adult subjects (PMID 19386527).

Pulsatility

A mechanistic concern with any continuously acting secretagogue is whether it flattens the natural pulsatile pattern of GH release. Investigators addressed this directly: a 2006 report concluded that pulsatile secretion of growth hormone persisted during continuous stimulation by CJC-1295 (PMID 17018654).

Limits of the evidence in Module 2: mechanism was characterised at the level of hormone and receptor, in rodents and in small groups of healthy adults. Nothing in these papers establishes what sustained axis activation does to tissue-level endpoints, and the serum protein changes described in 2009 were profile findings rather than demonstrated clinical effects (PMID 19386527).

Module 3: Reported Outcomes by Study

The table below summarises what each verified study examined. Doses and effects are attributed only where the cited paper's title and abstract scope support them; where a paper's abstract did not specify a dose, this course omits the number rather than estimating it.

Reading the human data carefully

The two 2006 human papers are the backbone of any discussion of "benefits", and both are endocrine-marker studies. One reported prolonged GH and IGF-I stimulation in healthy adults (PMID 16352683); the other examined whether that stimulation disturbed pulsatility and reported that pulses persisted (PMID 17018654). Neither measured body composition, strength, sleep quality, recovery, skin, injury healing, or longevity. The 2009 study extended the marker work into serum proteomics in normal adults (PMID 19386527), again without clinical outcome endpoints.

Limits of the evidence in Module 3: the human studies were conducted in healthy volunteers over short periods and reported biochemical endpoints. A rise in GH or IGF-I is a surrogate, not a demonstrated health benefit. The animal result that comes closest to a functional outcome — normalised growth — occurred in mice genetically lacking GHRH (PMID 16822960), a deficiency model that does not describe hormonally normal adults.

Module 4: CJC-1295 Side Effects: What Studies Report

Safety information in this literature is thin, and its thinness is itself a finding. The available human data come from small studies in healthy adults whose primary purpose was to characterise hormone secretion, not to detect uncommon harms.

What the controlled human studies covered

The 2006 study in healthy adults was a dosing study of GH and IGF-I responses; adverse events in such work are typically monitored as part of tolerability assessment, and researchers reported the endocrine findings as the primary result (PMID 16352683). The companion 2006 analysis of pulsatility likewise focused on secretory patterns rather than on harm detection (PMID 17018654). The 2009 serum protein study in normal adults reported changes in circulating protein profiles accompanying GH/IGF-1 axis activation, which the authors framed as biomarker findings rather than as clinical events (PMID 19386527).

Risks arising from product quality

A separate category of documented risk has nothing to do with pharmacology. A 2010 analytical report described the identification of CJC-1295 in an unknown pharmaceutical preparation (PMID 21204297), illustrating that material circulating outside regulated channels may carry no reliable statement of contents, concentration or purity. Anti-doping laboratories developed dedicated detection methods for the same reason: a 2019 paper published an LC-MS/MS method for confirming CJC-1295 abuse in equine plasma (PMID 30938069), and a companion 2019 paper described an immuno-PCR screen for CJC-1295 and other GHRH analogs in equine plasma (PMID 30489688).

Unsupervised use as described in a qualitative study

The 2016 netnographic study analysed online discussion among women using synthetic growth hormone secretagogue material including CJC-1295, describing how information and practices circulated in those communities (PMID 26771670). Self-reported accounts collected from forums are not adverse-event surveillance and cannot establish frequency, causation or severity.

Limits of the evidence in Module 4: there is no long-term safety trial in the verified literature, no published registry, and no dataset large enough to estimate the rate of uncommon events. Theoretical concerns that follow from sustained GH/IGF-I elevation — for example effects on glucose handling or on tissues sensitive to IGF-I — were not tested as endpoints in any of the papers cited here. Absence of reported harm in small short studies is not evidence of safety.

Module 5: Pharmacokinetics Where Data Exist

Duration of action

The central pharmacokinetic claim in this literature is prolonged exposure produced by albumin conjugation. The 2005 rat study identified CJC-1295 as a long-lasting GRF analog on the basis of sustained receptor activation (PMID 15817669). In humans, the 2006 JCEM study reported prolonged stimulation of GH and IGF-I secretion after administration in healthy adults (PMID 16352683), and the persistence of GH pulses under continuous stimulation was reported separately (PMID 17018654). Dosing frequency in the mouse work was once daily (PMID 16822960).

Detection windows

Analytical pharmacokinetics has been pursued mainly in the anti-doping setting. Researchers published an LC-MS/MS confirmation method for CJC-1295 in equine plasma in 2019 (PMID 30938069) and, in the same year, an immuno-PCR screening assay capable of detecting CJC-1295 and other GHRH analogs in equine plasma (PMID 30489688). These papers describe assay performance in horses; they were not designed as human pharmacokinetic studies.

Limits of the evidence in Module 5: the verified abstracts do not provide a numeric human half-life, clearance value or bioavailability figure, so none is stated here. Detection methods developed in equine plasma do not transfer automatically to human matrices, and no verified paper reports steady-state kinetics during repeated human dosing.

Module 6: Regulatory Status, Stated Factually

No approved product

CJC-1295 is not an approved medicine. It did not complete a development programme to marketing authorisation, and the human studies in this course were early-phase investigations in healthy volunteers (PMID 16352683). Separately approved products exist in the broader GHRH-analog space — tesamorelin is an approved GHRH analog for a specific indication — but that approval applies to tesamorelin, not to CJC-1295.

Research-use-only material

Material labelled CJC-1295 is generally distributed as research-use-only chemical, meaning it is not manufactured, tested or labelled to pharmaceutical standards for human administration. The practical consequence is documented in the analytical literature, where a preparation of unknown origin required laboratory work to establish that it contained CJC-1295 at all (PMID 21204297).

Compounding

In the United States, compounding pharmacies operate under statutory limits that generally require a bulk substance to be an approved-product ingredient, appear on a designated bulk substances list, or be the subject of an applicable monograph. Peptides that do not meet those criteria are not eligible for compounding. Regulators have also reviewed a number of peptide bulk substances and raised concerns about immunogenicity and characterisation for compounded peptides generally.

Sport

GHRH analogs are prohibited in sport under anti-doping rules, which is why detection assays were developed; the 2019 equine methods were explicitly framed around confirming and screening for CJC-1295 abuse (PMID 30938069, PMID 30489688).

Limits of the evidence in Module 6: regulatory classifications change, differ by country and are not determined by the scientific literature. Nothing in this module is legal advice.

What the Studies Did Not Test

• Clinical outcomes. No verified study measured body composition, muscle strength, fat loss, sleep architecture, injury recovery, skin appearance or athletic performance in humans.
• Long-term use. The human reports describe short investigations in healthy adults (PMID 16352683, PMID 17018654); multi-year exposure was not studied.
• Special populations. Older adults, adolescents, people with diabetes, cancer history, pituitary disease or pregnancy were not the subjects of the verified human studies.
• Combinations. No verified paper tested CJC-1295 alongside other secretagogues, growth hormone itself, or anabolic agents.
• Non-conjugated variants. The pharmacology papers characterised the albumin-binding bioconjugate (PMID 15817669); other marketed variants were not the tested article.
• Harm frequency. No study in this set was powered or designed to quantify adverse-event rates.

Read against that list, the honest summary is narrow: in rodents and in small groups of healthy adults, researchers reported that CJC-1295 activated the GHRH receptor and raised GH and IGF-I for a prolonged period while preserving pulsatility. Everything beyond that is extrapolation. This page is for educational purposes only and is not medical advice; consult a licensed physician about individual circumstances.

References

• Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog (Endocrinology, 2005)
• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (The Journal of Clinical Endocrinology and Metabolism, 2006)
• Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse (American Journal of Physiology. Endocrinology and Metabolism, 2006)
• Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog (The Journal of Clinical Endocrinology and Metabolism, 2006)
• Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects (Growth Hormone & IGF Research, 2009)
• Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation (Drug Testing and Analysis, 2010)
• Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions (Substance Use & Misuse, 2016)
• An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma (Drug Testing and Analysis, 2019)
• A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS (Drug Testing and Analysis, 2019)